170 related articles for article (PubMed ID: 21735820)
21. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
22. New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation.
Gunduz M; Argikar UA; Cirello AL; Dumouchel JL
Drug Metab Lett; 2018; 12(2):84-92. PubMed ID: 29886840
[TBL] [Abstract][Full Text] [Related]
23. Cloning and characterization of a canine UDP-glucuronosyltransferase.
Soars MG; Smith DJ; Riley RJ; Burchell B
Arch Biochem Biophys; 2001 Jul; 391(2):218-24. PubMed ID: 11437353
[TBL] [Abstract][Full Text] [Related]
24. N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-C]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases.
Yan Z; Caldwell GW; Gauthier D; Leo GC; Mei J; Ho CY; Jones WJ; Masucci JA; Tuman RW; Galemmo RA; Johnson DL
Drug Metab Dispos; 2006 May; 34(5):748-55. PubMed ID: 16455802
[TBL] [Abstract][Full Text] [Related]
25. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases.
Zhou J; Zhang J; Xie W
Curr Drug Metab; 2005 Aug; 6(4):289-98. PubMed ID: 16101569
[TBL] [Abstract][Full Text] [Related]
26. Drug glucuronidation by human renal UDP-glucuronosyltransferases.
McGurk KA; Brierley CH; Burchell B
Biochem Pharmacol; 1998 Apr; 55(7):1005-12. PubMed ID: 9605424
[TBL] [Abstract][Full Text] [Related]
27. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics.
Turgeon D; Carrier JS; Chouinard S; Bélanger A
Drug Metab Dispos; 2003 May; 31(5):670-6. PubMed ID: 12695357
[TBL] [Abstract][Full Text] [Related]
28. Expression of UDP-glucuronosyltransferase 1A6 isoform in Caco-2 cells stimulated with lipopolysaccharide.
Panaro MA; Cavallo P; Acquafredda A; Cianciulli A; Calvello R; Mitolo V
Innate Immun; 2010 Oct; 16(5):302-9. PubMed ID: 19710100
[TBL] [Abstract][Full Text] [Related]
29. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions.
Bock KW; Köhle C
Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343
[TBL] [Abstract][Full Text] [Related]
30. Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Tukey RH; Strassburg CP
Annu Rev Pharmacol Toxicol; 2000; 40():581-616. PubMed ID: 10836148
[TBL] [Abstract][Full Text] [Related]
31. Biosynthesis of Drug Glucuronide Metabolites in the Budding Yeast Saccharomyces cerevisiae.
Ikushiro S; Nishikawa M; Masuyama Y; Shouji T; Fujii M; Hamada M; Nakajima N; Finel M; Yasuda K; Kamakura M; Sakaki T
Mol Pharm; 2016 Jul; 13(7):2274-82. PubMed ID: 27241161
[TBL] [Abstract][Full Text] [Related]
32. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes.
Bourcier K; Hyland R; Kempshall S; Jones R; Maximilien J; Irvine N; Jones B
Drug Metab Dispos; 2010 Jun; 38(6):923-9. PubMed ID: 20304965
[TBL] [Abstract][Full Text] [Related]
33. Gender-dependent differences in uridine 5'-diphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics.
Liu W; Kulkarni K; Hu M
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1555-69. PubMed ID: 24011176
[TBL] [Abstract][Full Text] [Related]
34. Glucuronidation of 1'-hydroxyestragole (1'-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9.
Iyer LV; Ho MN; Shinn WM; Bradford WW; Tanga MJ; Nath SS; Green CE
Toxicol Sci; 2003 May; 73(1):36-43. PubMed ID: 12657745
[TBL] [Abstract][Full Text] [Related]
35. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family.
Ebner T; Burchell B
Drug Metab Dispos; 1993; 21(1):50-5. PubMed ID: 8095226
[TBL] [Abstract][Full Text] [Related]
36. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay.
Di Marco A; D'Antoni M; Attaccalite S; Carotenuto P; Laufer R
Drug Metab Dispos; 2005 Jun; 33(6):812-9. PubMed ID: 15788539
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide.
D'Andrea V; Pérez LM; Sánchez Pozzi EJ
Life Sci; 2005 Jun; 77(6):683-92. PubMed ID: 15921999
[TBL] [Abstract][Full Text] [Related]
38. Natural and synthetic inhibitors of UDP-glucuronosyltransferase.
Grancharov K; Naydenova Z; Lozeva S; Golovinsky E
Pharmacol Ther; 2001 Feb; 89(2):171-86. PubMed ID: 11316519
[TBL] [Abstract][Full Text] [Related]
39. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification.
Rowland A; Miners JO; Mackenzie PI
Int J Biochem Cell Biol; 2013 Jun; 45(6):1121-32. PubMed ID: 23500526
[TBL] [Abstract][Full Text] [Related]
40. Measurements of UDP- glucuronosyltransferase (UGT) activities.
Coffman BL; Rios GR; Tephly TR
Curr Protoc Toxicol; 2002; Chapter 4():Unit4.3. PubMed ID: 23045083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
